# reload+after+2024-01-20 08:43:08.761733
address1§2 Blue Hill Plaza
address2§3rd Floor
city§Pearl River
state§NY
zip§10965
country§United States
phone§914 347 4300
fax§914 347 4560
website§https://www.acorda.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.
fullTimeEmployees§111
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Ron  Cohen M.D.', 'age': 67, 'title': 'Founder, CEO, President & Director', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 984150, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael A. Gesser M.B.A.', 'age': 60, 'title': 'Chief Financial Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 459150, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kerry M. Clem', 'age': 53, 'title': 'Chief Commercial Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 592225, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert  Morales', 'age': 55, 'title': 'Interim Principal Accounting Officer, Principal Financial Officer, VP of Finance & Controller', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Felicia  Vonella', 'title': 'Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Neil S. Belloff Esq.', 'age': 63, 'title': 'General Counsel & Corporate Secretary', 'yearBorn': 1960, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tierney  Saccavino', 'title': 'Executive Vice President of Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Denise J. Duca', 'title': 'Executive Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andrew  Mayer J.D.', 'title': 'Senior Vice President', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Sofia  Ali', 'title': 'Senior VP of Operations & Strategic Planning', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§5
compensationRisk§7
shareHolderRightsRisk§7
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.451
priceToSalesTrailing12Months§0.162084
currency§USD
dateShortInterest§1702598400
forwardEps§-0.96
exchange§NMS
quoteType§EQUITY
shortName§Acorda Therapeutics, Inc.
longName§Acorda Therapeutics, Inc.
firstTradeDateEpochUtc§1139581800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§6677f3ed-ce73-34bc-a776-76e782fb0960
gmtOffSetMilliseconds§-18000000
recommendationMean§2.0
recommendationKey§buy
quickRatio§0.96
grossMargins§0.8237
ebitdaMargins§0.10354
trailingPegRatio§None
